{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:37:01Z","timestamp":1760146621697,"version":"build-2065373602"},"reference-count":40,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background\/Objectives: Anticoagulant therapy, particularly the use of direct oral anticoagulant agents (DOACs), is recommended for patients with nonvalvular atrial fibrillation (NVAF). This multicenter observational retrospective cohort study aimed to assess the efficacy and safety of DOACs compared to warfarin in Japanese patients aged 75 years and older with NVAF. Methods: Data from the Mie-Life Innovation Promotion Center Database were used to collect medical information on the patients. The cumulative incidences of clinically significant bleeding events and systemic embolic events (SEEs) were analyzed. Results: This study included 1787 older adult patients, of whom 1321 received DOACs (edoxaban: 428; apixaban: 586; dabigatran: 105; rivaroxaban: 202) and 466 receiving warfarin. There were no statistically significant differences in the cumulative incidence of bleeding events between the DOAC- and warfarin-treated groups. However, a statistically significant difference was observed for SEEs, with dabigatran showing a significantly lower incidence compared to warfarin. Conclusions: The incidence rates of bleeding events for individual DOACs were comparable to those for warfarin. Additionally, a history of vascular disorders was identified as a risk factor for bleeding events in the DOAC-treated group (hazard ratio (HR): 1.83, 95% confidence interval (CI): 1.16\u20132.88, p &lt; 0.01) and warfarin-treated group (HR: 1.80, 95% CI: 1.15\u20132.84, p &lt; 0.01). Based on real-world data, the overall efficacy and safety of DOACs were generally comparable to warfarin.<\/jats:p>","DOI":"10.3390\/pharmaceutics16121515","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:38:24Z","timestamp":1732523904000},"page":"1515","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Embolism and Clinically Significant Bleeding Events in Older Adults with Nonvalvular Atrial Fibrillation After Treatment with Direct Oral Anticoagulants and Warfarin: A Retrospective Cohort Study in Japan"],"prefix":"10.3390","volume":"16","author":[{"given":"Daichi","family":"Yaguchi","sequence":"first","affiliation":[{"name":"Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"},{"name":"Medical Affairs Department, Alnylam Japan KK, Chiyoda-ku, Tokyo 100-6211, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-2745-5246","authenticated-orcid":false,"given":"Shoji","family":"Sera","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"},{"name":"Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Okada","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"},{"name":"Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2325-7110","authenticated-orcid":false,"given":"Yuki","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital, Tsu 514-8507, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2959-6077","authenticated-orcid":false,"given":"Satoshi","family":"Tamaru","sequence":"additional","affiliation":[{"name":"Clinical Research Support Center, Mie University Hospital, Tsu 514-8507, Mie, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Nagai","sequence":"additional","affiliation":[{"name":"Laboratory of Regulatory Science, Faculty of Pharmacy, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"},{"name":"Research Institute of Pharmaceutical Sciences, Musashino University, Nishi-tokyo, Tokyo 202-8585, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1253\/circj.CJ-20-1212","article-title":"JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias","volume":"86","author":"Ono","year":"2022","journal-title":"Circ. J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2169\/naika.108.196","article-title":"Epidemiology of atrial fibrillation: Atrial fibrillation as a common disease","volume":"108","author":"Masaharu","year":"2019","journal-title":"J. Jpn. Soc. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: The Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"ref_4","unstructured":"Cohen, L.S. (1992). Stroke. Yale University School of Medical Heart Book, William Morrow and Co."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJM199211123272002","article-title":"Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation","volume":"327","author":"Ezekowitz","year":"1992","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation\u2014The J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1161\/STROKEAHA.113.000990","article-title":"Dabigatran versus warfarin: Effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation","volume":"44","author":"Hori","year":"2013","journal-title":"Stroke"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1161\/STROKEAHA.113.002968","article-title":"Rivaroxaban for stroke prevention in East Asian patients from the ROCKET AF trial","volume":"45","author":"Wong","year":"2014","journal-title":"Stroke"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","article-title":"Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: A subanalysis of the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"168","author":"Goto","year":"2014","journal-title":"Am. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1253\/circj.CJ-15-1082","article-title":"Edoxaban vs. warfarin in East Asian patients with atrial fibrillation\u2014An ENGAGE AF-TIMI 48 Subanalysis","volume":"80","author":"Yamashita","year":"2016","journal-title":"Circ. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1253\/circj.CJ-22-0023","article-title":"10-year trends of antithrombotic therapy status and outcomes in Japanese atrial fibrillation patients\u2014The Fushimi AF Registry","volume":"86","author":"Akao","year":"2022","journal-title":"Circ. J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1253\/circj.CJ-16-1337","article-title":"Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients\u2014Fushimi AF Registry","volume":"81","author":"Yamashita","year":"2017","journal-title":"Circ. J."},{"key":"ref_17","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, October 20). Edoxaban Tosilate Hydrate, Pharmaceutical Review Report. Available online: https:\/\/www.pmda.go.jp\/drugs\/2014\/P201400133\/430574000_22300AMX00547_A100_1.pdf."},{"key":"ref_18","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, October 20). Apixaban, Pharmaceutical Review Report. Available online: https:\/\/www.pmda.go.jp\/drugs\/2012\/P201200166\/670605000_22400AMX01496_A100_1.pdf."},{"key":"ref_19","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, October 20). Dabigatran Etexilate Methanesulfonate, Pharmaceutical Review Report. Available online: https:\/\/www.pmda.go.jp\/drugs\/2011\/P201100019\/530353000_22300AMX00433000_A100_1.pdf."},{"key":"ref_20","unstructured":"Pharmaceuticals and Medical Devices Agency (2024, October 20). Rivaroxaban, Pharmaceutical Review Report. Available online: https:\/\/www.pmda.go.jp\/drugs\/2015\/P20150917002\/630004000_22400AMX00041_A100_2.pdf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e063623","DOI":"10.1136\/bmjopen-2022-063623","article-title":"Incidence of stroke, systemic embolism and bleeding events in patients without anticoagulation based on real-world data in Japan: A retrospective cohort study","volume":"12","author":"Tanizawa","year":"2022","journal-title":"BMJ Open"},{"key":"ref_22","unstructured":"Mie-LIP DB (2023, June 30). Mie-LIP DB Center in Clinical Research Support Center, Mie University Hospital. Available online: http:\/\/www.mie-cts.net\/top\/mie-lip.htm."},{"key":"ref_23","unstructured":"(2024, October 20). Act on Assurance of Medical Care for Elderly People (Act No. 80 of 1982). Japan. Available online: https:\/\/laws.e-gov.go.jp\/law\/357AC0000000080."},{"key":"ref_24","unstructured":"Daiichi Sankyo Co., Ltd. (2014). Lixiana (Edoxaban) [Package Insert], Daiichi Sankyo Co., Ltd."},{"key":"ref_25","unstructured":"Pfizer Japan Inc (2013). Eliquis (Apixaban) [Package Insert], Pfizer Japan Inc."},{"key":"ref_26","unstructured":"Boehringer Ingelheim International GmbH (2011). Pradaxa (Dabigatran Etexilate) [Package Insert], Nippon Boehringer Ingelheim Co., Ltd."},{"key":"ref_27","unstructured":"Bayer Yakuhin, Ltd. (2012). Xarelto (Rivaroxaban) [Package Insert], Bayer Yakuhin, Ltd."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely-available easy-to-use software \u201cEZR\u201d (Easy R) for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/joa3.12520","article-title":"Safety and effectiveness of edoxaban in Japanese patients with non-valvular atrial fibrillation: Final report of a two-year postmarketing surveillance study (ETNA-AF-Japan)","volume":"37","author":"Yamashita","year":"2021","journal-title":"J. Arrhythm."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ikeda, T., Ogawa, S., Kitazono, T., Nakagawara, J., Minematsu, K., Miyamoto, S., Murakawa, Y., Iwashiro, S., Okayama, Y., and Sunaya, T. (2021). Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0251325"},{"key":"ref_31","first-page":"1116","article-title":"Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population","volume":"24","author":"Gupta","year":"2018","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of Rivaroxaban vs Apixaban with Major Ischemic or Hemorrhagic Events in Patients with Atrial Fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/01.CIR.0000131515.03336.f8","article-title":"Role of Endothelial Dysfunction in Atherosclerosis","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in Patients With a Recent Acute Coronary Syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and Challenges in Translating the Biology of Atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of Potentially Modifiable Risk Factors Associated with Myocardial Infarction in 52 Countries (the INTERHEART Study): Case-Control Study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"231","DOI":"10.5649\/jjphcs.49.231","article-title":"Effect of Proton Pump Inhibitor Combination with Direct Oral Anticoagulants on the Onset Timing of Central Nervous System Bleeding Disorder\u2014Analysis of the Japanese Adverse Drug Event Reporting System","volume":"49","author":"Shimada","year":"2023","journal-title":"Jpn. J. Pharm. Health Care Sci."},{"key":"ref_38","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) (2024, November 11). Guidelines for Implementation of Pharmacoepidemiological Studies in Drug Safety Evaluation Using Medical Information Databases, Version 1. 31 March 2014. Available online: https:\/\/www.pmda.go.jp\/files\/000240951.pdf."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jjcc.2016.10.015","article-title":"Usefulness of a healthcare database for epidemiological research in atrial fibrillation","volume":"70","author":"Koretsune","year":"2017","journal-title":"J. Cardiol."},{"key":"ref_40","first-page":"87","article-title":"The Epidemiological Study of Venous Thromboembolism and Bleeding Events Using a Japanese Healthcare Database\u2014Validation Study","volume":"17","author":"Yamaguchi","year":"2015","journal-title":"Jpn. J. Drug Inform."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/12\/1515\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:39:02Z","timestamp":1760114342000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/16\/12\/1515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["pharmaceutics16121515"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics16121515","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}